The more pertinent question may be why Moderna chose to release results from its vaccine trial Monday. Testing for neutralizing antibodies is more time-consuming than other antibody tests and must be done in a biosecurity level 3 laboratory.
The benchmark index surged more than 3 per cent on Monday, boosted by Moderna's promising early-stage data for a Covid-19 vaccine and Federal Reserve Chair Jerome Powell's pledge over the weekend to support the economy as needed until the crisis has passed. Moderna was first out of the gate with human trials starting in March.
Two weeks after patients received the final dose at the 25 and 100 mcg levels, eight saw their antibody levels rise to about the same level as patients who already recovered from COVID-19, according to the report.
The new technology depends on the body's own cells to produce viral proteins resembling the "spikes" of the real virus, using virus RNA to cause this protein production that then triggers the body to produce its own antibodies blocking the spike from doing its dirty work. So the best-case scenario is that the vaccine for the novel coronavirus which has caused this worldwide pandemic might have a vaccine this year or early 2021. The vaccine produced antibodies in all 45 healthy volunteers who participated in the study. The company has more than 20 drugs in the pipeline, including potential treatments for rare diseases and cancer, and nine possible vaccines against various viruses.
According to CNBC news, scientists hope the antibodies will provide some degree of protection against getting infected, "but they can't say that definitively yet since it hasn't been studied and some patients appear to have been reinfected after recovering from the virus".
It is being developed in a partnership with the National Institute of Allergy and Infectious Disease headed by Anthony Fauci and the clinical test was carried out by the National Institutes of Health.
The interim data revealed by Moderna reports no serious adverse effects from the vaccine, across all dose cohorts. The company has also not said how it plans to make money on the vaccine.
The company put out its press release at 7:30 a.m., two hours before the stock market opened, and received quick coverage from most major media outlets. There is still a lot of work to be done, and a lot of unknowns, when it comes to demonstrating how safe and effective this vaccine. "They have not published any of that".
"I would like to see the data to make my own interpretation of the data".
"I think we're going to have a vaccine much sooner rather than later", Trump said. Robinson is a former director of the Biomedical Advanced Research and Development Authority, a USA government agency partnered with Moderna to help with develop its vaccine. In a statement issued in January about a Phase 1 trial for its cytomegalovirus (CMV) vaccine, it quantified how far over baseline measures antibody levels rose in vaccines.
Due to an easing of FDA regulations in regards to medicines, tests, and equipment related to COVID-19, the approval process for Moderna's potential COVID-19 vaccine is moving rapidly.